CCSI has identified what is known as "chromogenic diseases". While technically this is not a defined medical term, it describes diseases which the Company believes can be diagnosed or monitored by the coloration of human skin, tissue or fluids. There are many of these diseases such as anemia, hepatitis, tuberculosis, forms of malignancy evaluated through biopsy tissue and different fluid laboratory analyses.
To develop monitoring instruments for these medical applications it would require extensive clinical trials to obtain separate FDA clearances for each monitoring system. So CCSI focused initially on one particular disease which was probably influenced by the personal experience of Darby MacFarlane, the CEO of CCSI. This particular experience was the birth of a premature child who as an infant lived through the nightmare of this particular disease which is called Bilirubin infant jaundice.
This disease affects over half of all babies born and nearly 100% of all premature children. Every infant born is monitored for it. It is a liver-related disease and fundamentally occurs in varying degrees within the first two weeks of a child's life when the liver is trying to work on its own independent of the mother. If the liver doesn't take over quickly enough and the disease is not caught in time and then treated by phototherapy or exchange transfusion, the results can lie varying degrees of nervous system damage/or brain damage called Kernicterus. If left untreated, it is ultimately fatal.
Scientists learned a long time ago that the disease causes a yellow staining of any affected cells. If an autopsy is performed on a child who dies from kernicterus the brain cells will be stained a yellow color. The medical community also very early on observed that the disease affected the yellow color of the baby's skin. However, the only method accurate enough to monitor it was a blood test, often taken many times a day, where a laboratory spectrophotometer would measure the stained color of the blood serum to determine in mg/dl the amount of bilirubin present.
Now, with Chromatics' technology, it is possible for the health care professional to decrease blood tests and monitor the disease by using a light sensor which measure the skin of the baby's body and the incremental yellow content within this skin, painlessly and non-invasively. This is a tremendous advantage as the extensive blood drawing from infants is a truly savage procedure.
Many newborns, especially preemies, don't have fully formed veins, so to obtain the blood samples the doctors or nurses have to incise and squeeze the blood out which is a brutal process, leaving scars and moreover is labor intensive, especially when this procedure occurs in a good size nursery with an average of 30 babies needing multiple tests per day.
CCSI has already begun shipping Colormate TLc machines to its partner Datex-Ohmeda. I expect those initial orders to be surpassed soon:
biz.yahoo.com
I found this information in a post at Yahoo. While no one can know if it is accurate information... I can hope!
This company just moved from an intellectual property company to a viable, legitimate, fully productive manufacturer of a great product. They now have sales revenues and will be profitable this quarter probably, next quarter for sure. They are continuing to fulfill the terms of their agreement with Datex-Ohmeda and the next step is the current delivery (per contract) of another 500 units along with around 200,000 more lensettes. That's gotta be over $2million in additional revenue:
messages.yahoo.com |
